Skip to main content
CC logo

CC · Chemours Co

Track CC — free
$11.91 -0.19 (-1.53%)
Market Cap
$1.82B
Shares
150.53M
Volume · Nov 19 254.75K Avg daily vol (3M) 2.1M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.09 Open$12.18 Day$11.75–12.32 52W close$10.48–27.94 Avg vol 30d2.5M Short int14.5M · 9.7% of shares · 6.9d Short vol62% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 19, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 18
Current report 8-K Events of Nov 16
Chemours General Counsel Kristine Wellman to retire; Amy Rocklin named successor

Kristine Wellman, Senior Vice President, General Counsel & Corporate Secretary, plans to retire, and Amy M. Rocklin will succeed her effective January 4, 2027. Wellman will then serve as Senior Vice President, Senior Counsel until May 7, 2027.

Director or officer change, or executive pay
3 source passages
Kristine M. Wellman, Senior Vice President, General Counsel & Corporate Secretary, plans to retire from her position, and the Company has selected Amy M. Rocklin to succeed Ms. Wellman effective January 4, 2027 (the “Transition Date”) Following the Transition Date, Ms. Wellman will serve as Senior Vice President, Senior Counsel until May 7, 2027. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter sales rose 3% to $1.5 billion

Chemours reported third-quarter net sales of $1.5 billion, up 3%. Titanium Technologies Adjusted EBITDA rose to $85 million and margin to 13%, while Thermal & Specialized Solutions Adjusted EBITDA fell to $136 million and margin to 27%.

Revenue $1.54B ▲ 3.0% Net income $196M ▲ 326.1% Diluted EPS $1.29 ▲ 316.1%
Read from the MD&A section
3 source passages
Our net sales increased by $45 million (or 3%) to $1.5 billion for the three months ended September 30, 2026, compared with net sales of $1.5 billion for the same period in 2025. For the three months ended September 30, 2026 segment Adjusted EBITDA increased by $60 million (or over 100%) to $85 million and Adjusted EBITDA margin increased by approximately 900 basis points to 13%, compared with segment Adjusted EBITDA of $25 million and Adjusted EBITDA margin of 4% for the same period in 2025. For the three months ended September 30, 2026, segment Adjusted EBITDA decreased by $58 million (or 30%) to $136 million and Adjusted EBITDA margin decreased by approximately 800 basis points to 27%, compared with segment Adjusted EBITDA of $194 million and Adjusted EBITDA margin of 35% for the same period in 2025. Open the document at this passage
Nov 3
Annual report 10-K/A Ended Dec 31
Disclosure controls were ineffective due to omitted internal-control report

Chemours’ disclosure controls were not effective as of December 31, 2025 because an administrative error omitted its internal-control report. The issue persisted until the third quarter of 2026, when additional reviews were implemented; consolidated financial statements were unaffected.

Read from the first part of this long document
3 source passages
Amendment No. 1 amends the Annual Report on Form 10-K of The Chemours Company (the “Company” or “Chemours”) for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2026 (the “Original Filing”). The ineffectiveness of the Company’s disclosure controls and procedures existed from December 31, 2025 until the third quarter of 2026. In addition to the Company’s existing disclosure controls and procedures, during the third quarter of 2026, management implemented additional review procedures to provide reasonable assurance over the completeness of the non-financial statement disclosure requirements of the applicable SEC form. This Amendment No. 1 does not affect the Company’s consolidated financial statements included in the Original Filing. Open the document at this passage
Nov 3
Earnings call
Adjusted EBITDA $200 million; outlook $775 million to $800 million

Chemours reported adjusted EBITDA of $200 million, at the high end of guidance. It expects 2026 adjusted EBITDA of $775 million to $800 million, free cash flow conversion of 15% to 20%, and net leverage below 4.2 times adjusted EBIT.

5 source passages
Adjusted EBITDA was $200 million at the high end of our guidance range, with all businesses contributing above expectations. we now expect net sales to grow around 2% compared with 2025 and adjusted EBITDA to now be between $775 million and $800 million. we now anticipate free cash flow conversion to be between 15% to 20%, which reflects capital expenditures between $220 million and $230 million. Our net leverage ratio is now expected to be below 4.2 times adjusted EBIT at the end of 2026. We remain focused on controlling what we can control and are confident in the cost measures we have taken and the improvements we are driving across our operational circuit through the Chemours business system to strengthen our resilience and execution. Open the document at this passage
Nov 2
Current report 8-K
Third-quarter sales rise as adjusted EBITDA reaches $200 million

Chemours reported third-quarter Net Sales of $1.5 billion and Adjusted EBITDA of $200 million, while net income reached $196 million. For 2026, Net Sales are expected to grow approximately 2%, with Adjusted EBITDA of $775 million to $800 million.

Financial results Read from the first part of this long document
5 source passages
The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”), today announced its financial results for the third quarter 2026. Net Sales of $1.5 billion, up slightly from the prior-year quarter, reflecting an approximately 10% year-over-year pricing increase in TT and 26% year-over-year growth in APM Performance Solutions. Adjusted EBITDA for the third quarter of 2026 was $200 million, compared with $189 million in the prior-year quarter. Net Income attributable to Chemours of $196 million, or $1.29 per diluted share, compared with Net Income attributable to Chemours of $46 million, or $0.31 per diluted share, in the corresponding prior-year quarter. The Company expects 2026 Net Sales to grow approximately 2% over 2025, with Adjusted EBITDA between $775 million and $800 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.84B
Trailing 12 months
Net income (TTM)
−$154.00M
Trailing 12 months
Revenue growth YoY
+3.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
11.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$3.13B
Latest balance sheet
Dividend yield
2.9%
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
+10.6%
Trailing year
Short interest
9.7%
Latest settlement · 6.9 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Chemours reported Q2 Adjusted EBITDA of $247M (down 5% YoY) and reaffirmed full-year 2026 Adjusted EBITDA guidance of $775M–$825M, but guided Q3 TSS net sales down mid-teens to 20% sequentially due to aftermarket de-stocking; the company delivered a 128% YoY jump in free cash flow, reduced net leverage to 4.4x, and booked a $266M gain from the Kuan Yin land sale used for debt paydown.

Bullish
  • + Free cash flow surged 128% YoY with conversion at 46%, supporting debt reduction
  • + Repaid an incremental $270M of 2028 Term Loan, $103M above prior guidance
  • + TT pricing momentum with three TiO2 increases YTD totaling ~5% price increase
  • + APM Performance Solutions sales grew 8% YoY on data center/semiconductor momentum
  • + Full-year 2026 Adjusted EBITDA guidance of $775M–$825M reaffirmed with margin expansion
Bearish
  • − Q2 net loss attributable to Chemours of $274M, though narrower YoY
  • − Q3 TSS net sales guided down mid-teens to 20% sequentially on aftermarket de-stocking
  • − TSS aftermarket volume down ~25% YoY with elevated inventory overhang
  • − APM Q2 Adjusted EBITDA fell 48% YoY on Capstone closure and Washington Works outage costs
  • − Net leverage remains elevated at 4.4x, still above 3.8x year-end target

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −34%
below
Price vs 50-day avg −11%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 9%
near low
Momentum
relative strength
Weak
1-month return −7%
trailing
6-month return −45%
trailing
YTD return +3%
this year
Relative strength −42%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $14 › 200d $18 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +59 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.66% of shares out · ▼ -2.1% MoM · 6.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
449 holders — mid 3-yr range
Squeeze score 70
high risk · 0–100
Fundamentals
Weak
Revenue growth +7%
Y/Y
Gross margin 14%
contracting
EPS growth −659%
Y/Y
Free cash flow $51.0M
Buyback $441.0M
remaining
Balance sheet $3.5B
net debt
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −57%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 2, 2026
fourth quarter
Consolidated Adjusted EBITDA Non-GAAP $160M – $185M
Corporate Expenses $40M – $45M
2026
Net Sales Lowered 2%
Aug 5, 2026 1% – 5% changed to Nov 2, 2026 2%
Overall Free Cash Flow Conversion Non-GAAP Initiated at least 15%
Year Ending December 31, 2026
Restructuring, transaction, and other costs, net Initiated $210M
Adjusted Net Income Non-GAAP Initiated $110M – $120M
Interest expense, net Initiated $275M – $280M
Depreciation and amortization Initiated $320M
All remaining provision for income taxes Initiated $70M – $80M
Free Cash Flow Conversion 15% – 20%
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

TSS's adjusted EBITDA · third quarter $125M – $140M
TT's adjusted EBITDA · third quarter $70M – $80M
APM's adjusted EBITDA · third quarter $20M – $30M
Consolidated adjusted EBITDA · third quarter $175M – $205M
Corporate expenses · third quarter $40M – $45M
Free cash flow · third quarter at least $50M
Adjusted EBITDA · 2026 full year $775M – $825M
Capital expenditures · third quarter $65M
Free cash flow conversion · full year at least 25%
Annual adjusted EBITDA · longer term at least $1B
Free cash flow conversion · longer term at least 40%
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
TSS's adjusted EBITDA · third quarter $125M – $140M
Corporate expenses · third quarter $40M – $45M
Consolidated adjusted EBITDA · third quarter $175M – $205M
TT's adjusted EBITDA · third quarter $70M – $80M
Free cash flow · third quarter at least $50M
Capital expenditures · third quarter $65M
Guided vs delivered · last 1 settled
Full year sales full year
guided $5.7B – $5.8B
$5.81B Beat +1.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−34% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
9% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $14 › 200d $18 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +59 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.66% of shares out · ▼ -2.1% MoM · 6.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
449 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $10 Now $12 · 9% Range high $28
vs 200-day avg -34% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted diluted earnings per share of common stock non-GAAP $0.47 Six Months Ended June 30, 2026 —
Adjusted EBITDA non-GAAP 733M Twelve Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
Adjusted Net Income 105M (non-GAAP)
-1M Net income attributable to non-controlling interests
+273M Interest expense, net
+320M Depreciation and amortization
+36M All remaining provision for income taxes
= Adjusted EBITDA 733M
Adjusted Net Income non-GAAP $72M Six Months Ended June 30, 2026 —
Advanced Performance Materials Adjusted EBITDA non-GAAP 26M Three Months Ended June 30, 2026 —
APM Performance Solutions Net Sales 142M Q2 2026 —
Capital expenditures $44M the second quarter of 2026 —
Consolidated gross debt 3.9B As of June 30, 2026 —
Corporate Expenses 42M Q2 2026 —
Free Cash Flow Conversion non-GAAP 5% Six Months Ended June 30, 2026 —
Free Cash Flows non-GAAP $21M Six Months Ended June 30, 2026 —
Freon™ Refrigerants Net Sales (TSS) 150M Q2 2026 —
Operating cash flows $158M the second quarter of 2026 —
Opteon™ Refrigerants Net Sales (TSS) 337M Q2 2026 —
Thermal & Specialized Solutions Adjusted EBITDA non-GAAP 213M Three Months Ended June 30, 2026 —
Titanium Technologies Adjusted EBITDA non-GAAP 48M Three Months Ended June 30, 2026 —
Total liquidity 1.6B As of June 30, 2026 —
TSS Adjusted EBITDA Margin non-GAAP 36% Q2 2026 —
TT TiO2 Pigment Net Sales 639M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Specialty Chemicals — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CC
Chemours Co
this stock
$1.82B +2.5% +7.4% — 9.7%
LIN
Linde PLC
$235.12B +20.1% +3.0% 34.0 1.4%
AIQUF
L Air Liquide SA
$132.78B +10.8% — — 0.0%
ECL
Ecolab Inc.
$84.33B +14.5% +2.2% 40.9 1.5%
SHW
Sherwin Williams Co
$83.73B +7.0% +2.1% 31.9 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
449
% held
86.9%
Net QoQ
-5.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
293
View
Short & Settlement
Short Interest Falling
Shares short
14.5M
Days to cover
6.9d
Change
-310.1K sh
View
Short Volume
Short vol %
62%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
61.4K
Value
$819.3K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
35.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Michael C. Burgess
Amount
$15.0K–$50.0K
Traded
Aug 9, 2023
View
Financials
Financials
Revenue (FY)
$5.8B
Net income (FY)
$-386.0M
EPS diluted
$-2.57
View
Buybacks
Authorized
$750.0M
Remaining
$441.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 18, 2026
This year
20

Kristine Wellman, Senior Vice President, General Counsel & Corporate Secretary, plans to retire, and Amy M. Rocklin will succeed her effective January 4, 2027. Wellman will then serve as Senior Vice President, Senior Counsel until May 7, 2027.

View
Proposed Sales
Value
$150.0K
Shares
7.5K
Filed
Nov 6, 2024
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Chemours Launches Faizeon™ Two-Ph…
Published
Nov 2, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
CC -11.9% -6.6% -45.4% -10.6% +2.5%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -8.0% -1.0% -42.0% -7.3% -4.5%

Capital returns

Latest dividend
$0.088 / share · ex Nov 16, 2026
Cut 64.8%
Paid (TTM)
$0.352 / share · 4 payouts
Dividend yield (TTM, derived)
2.91%
Full dividend history
Buyback program · as of Dec 31, 2025
Authorized
$750.00M
Spent (derived)
$309.00M
Remaining
$441.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1627223 CUSIP 163851108 13F (30d) 463 filings 395 filers Visit website Investor relations